---
schema_version: "secwatch.filing_event.v1"
accession: "0001539497-24-000104"
form_type: "8-K"
ticker: null
cik: "0001358403"
company_name: "BELLICUM PHARMACEUTICALS, INC"
filed_at: "2024-01-24T23:59:59+00:00"
generated_at: "2026-06-06T19:09:39.321270+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bellicum adjourns asset-sale special meeting for lack of quorum; issues super-voting share to director

## Summary
- Special meeting to approve sale of assets (CaspaCIDe, iMC, GoCAR-T, Rimiducid) to MD Anderson and dissolution adjourned; only 4,132,740 shares present, short of quorum.
- Issued one super-voting share to director Richard A. Fair for $0.01; holder casts votes proportionate to common stock votes at adjourned meeting.
- Bylaws amended: quorum now requires majority of voting power present, not majority of outstanding shares.
- No financial terms of asset sale disclosed; dissolution plan contingent on stockholder approval.

## SEC filing metadata
- accession: 0001539497-24-000104
- form_type: 8-K
- cik: 0001358403
- company_name: BELLICUM PHARMACEUTICALS, INC
- filed_at: 2024-01-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.02, 5.03, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1358403/000153949724000104/0001539497-24-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1358403/000153949724000104/n3936_x2-8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001539497-24-000104
- JSON: https://secwatch.observer/filing/0001539497-24-000104.json
- Plain text: https://secwatch.observer/filing/0001539497-24-000104.txt

## Key facts
- Governance Changes
  BELLICUM PHARMACEUTICALS, INC: Amended Article III, Section 8 of bylaws to change quorum requirement to a majority of voting power rather than a majority of outstanding shares (effective 2024-01-24).
  - Change: bylaw amendment
  - Effective: 2024-01-24
  source text: On January 24, 2024, the Board approved the amendment of Article III, Section 8 of the Company’s bylaws to enable the holders of a majority of the voting power of, rather than the majority of, the outstanding shares of stock of the Company entitled to vote at a meeting of stockholders to constitute a quorum for the transaction of business.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1358403/000153949724000104/0001539497-24-000104-index.htm
- Governance Changes
  BELLICUM PHARMACEUTICALS, INC: Filed Certificate of Designation for Series A Junior Preferred Stock (Super-Voting Share) (effective 2024-01-24).
  - Change: charter amendment
  - Effective: 2024-01-24
  source text: On January 24, 2024, the Company filed a Certificate of Designation of Series A Junior Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware with respect to the Super-Voting Share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1358403/000153949724000104/0001539497-24-000104-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.